| pubmed-article:19513296 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:19513296 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:19513296 | lifeskim:mentions | umls-concept:C0030567 | lld:lifeskim |
| pubmed-article:19513296 | lifeskim:mentions | umls-concept:C0165921 | lld:lifeskim |
| pubmed-article:19513296 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:19513296 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:19513296 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:19513296 | pubmed:dateCreated | 2009-6-10 | lld:pubmed |
| pubmed-article:19513296 | pubmed:abstractText | A carboxy-O-methyl transferase inhibitor entacapone has been introduced as an adjuvant drug for Parkinson disease (PD) patients. Although clinical trials reported beneficial role of entacapone, a long-term trial over 3 years failed to show significant effect. The goals of this study were to evaluate the clinical benefit and the efficacy of entacapone in an open clinical practice. | lld:pubmed |
| pubmed-article:19513296 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19513296 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19513296 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19513296 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19513296 | pubmed:language | eng | lld:pubmed |
| pubmed-article:19513296 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:19513296 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
| pubmed-article:19513296 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:19513296 | pubmed:issn | 1738-6586 | lld:pubmed |
| pubmed-article:19513296 | pubmed:author | pubmed-author:JeonBeom SBS | lld:pubmed |
| pubmed-article:19513296 | pubmed:author | pubmed-author:ImJoo-HyukJH | lld:pubmed |
| pubmed-article:19513296 | pubmed:author | pubmed-author:LeeWon YongWY | lld:pubmed |
| pubmed-article:19513296 | pubmed:author | pubmed-author:KimJae WooJW | lld:pubmed |
| pubmed-article:19513296 | pubmed:author | pubmed-author:AhnTae-BeomTB | lld:pubmed |
| pubmed-article:19513296 | pubmed:author | pubmed-author:LeeMyoung... | lld:pubmed |
| pubmed-article:19513296 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:19513296 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:19513296 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:19513296 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:19513296 | pubmed:pagination | 82-5 | lld:pubmed |
| pubmed-article:19513296 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:19513296 | pubmed:articleTitle | One-year open-label study of entacapone in patients with advanced Parkinson disease. | lld:pubmed |
| pubmed-article:19513296 | pubmed:affiliation | Department of Neurology, Kyung Hee University College of Medicine, Korea. | lld:pubmed |
| pubmed-article:19513296 | pubmed:publicationType | Journal Article | lld:pubmed |
